AIM: To evaluate the effect of orally administered plecanatide or dolcanatide, analogs of uroguanylin, on amelioration of colitis in murine models. METHODS: The cyclic guanosine monophosphate (cGMP) stimulatory potency of plecanatide and dolcanatide was measured using a human colon carcinoma T84 cell-based assay. For animal studies all test agents were formulated in phosphate buffered saline. Sulfasalazine or 5-amino salicylic acid (5-ASA) served as positive controls. Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice. Additionally, the effect of orally administered plecanatide on the spontaneous colitis in T-cell receptor alpha knockout (TCRα(-/-)) mice was also examined. Amelioration of colitis was assessed by monitoring severity of colitis, disease activity index and by histopathology. Frozen colon tissues were used to measure myeloperoxidase activity. RESULTS: Plecanatide and dolcanatide are structurally related analogs of uroguanylin, which is an endogenous ligand of guanylate cyclase-C (GC-C). As expected from the agonists of GC-C, both plecanatide and dolcanatide exhibited potent cGMP-stimulatory activity in T84 cells. Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05). Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA. Plecanatide also effectively ameliorated colitis in TCRα(-/-) mice, a model of spontaneous colitis. As dolcanatide exhibited higher resistance to proteolysis in simulated gastric and intestinal juices, it was selected for further studies. CONCLUSION: This is the first-ever study reporting the therapeutic utility of GC-C agonists as a new class of orally delivered and mucosally active drug candidates for the treatment of inflammatory bowel diseases.
AIM: To evaluate the effect of orally administered plecanatide or dolcanatide, analogs of uroguanylin, on amelioration of colitis in murine models. METHODS: The cyclic guanosine monophosphate (cGMP) stimulatory potency of plecanatide and dolcanatide was measured using a humancolon carcinoma T84 cell-based assay. For animal studies all test agents were formulated in phosphate buffered saline. Sulfasalazine or 5-amino salicylic acid (5-ASA) served as positive controls. Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice. Additionally, the effect of orally administered plecanatide on the spontaneous colitis in T-cell receptor alpha knockout (TCRα(-/-)) mice was also examined. Amelioration of colitis was assessed by monitoring severity of colitis, disease activity index and by histopathology. Frozen colon tissues were used to measure myeloperoxidase activity. RESULTS:Plecanatide and dolcanatide are structurally related analogs of uroguanylin, which is an endogenous ligand of guanylate cyclase-C (GC-C). As expected from the agonists of GC-C, both plecanatide and dolcanatide exhibited potent cGMP-stimulatory activity in T84 cells. Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05). Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA. Plecanatide also effectively ameliorated colitis in TCRα(-/-) mice, a model of spontaneous colitis. As dolcanatide exhibited higher resistance to proteolysis in simulated gastric and intestinal juices, it was selected for further studies. CONCLUSION: This is the first-ever study reporting the therapeutic utility of GC-C agonists as a new class of orally delivered and mucosally active drug candidates for the treatment of inflammatory bowel diseases.
Authors: Shehzad Z Sheikh; Refaat A Hegazi; Taku Kobayashi; Joseph C Onyiah; Steven M Russo; Katsuyoshi Matsuoka; Antonia R Sepulveda; Fengling Li; Leo E Otterbein; Scott E Plevy Journal: J Immunol Date: 2011-03-28 Impact factor: 5.422
Authors: Shaival H Davé; Jeremy S Tilstra; Katsuyoshi Matsuoka; Fengling Li; Richard A DeMarco; Donna Beer-Stolz; Antonia R Sepulveda; Mitchell P Fink; Michael T Lotze; Scott E Plevy Journal: J Leukoc Biol Date: 2009-05-19 Impact factor: 4.962
Authors: Erik S Blomain; Jieru E Lin; Crystal L Kraft; Urszula T Trela; Justin M Rock; Amanda S Aing; Adam E Snook; Scott A Waldman Journal: Expert Rev Clin Pharmacol Date: 2013-08-24 Impact factor: 5.045
Authors: Refaat A F Hegazi; Kavitha N Rao; Aqila Mayle; Antonia R Sepulveda; Leo E Otterbein; Scott E Plevy Journal: J Exp Med Date: 2005-12-19 Impact factor: 14.307
Authors: Amanda M Pattison; Erik S Blomain; Dante J Merlino; Fang Wang; Mary Ann S Crissey; Crystal L Kraft; Jeff A Rappaport; Adam E Snook; John P Lynch; Scott A Waldman Journal: Infect Immun Date: 2016-09-19 Impact factor: 3.441
Authors: Peng Li; Evan Wuthrick; Jeff A Rappaport; Crystal Kraft; Jieru E Lin; Glen Marszalowicz; Adam E Snook; Tingting Zhan; Terry M Hyslop; Scott A Waldman Journal: Cancer Res Date: 2017-09-15 Impact factor: 12.701
Authors: Bianca N Islam; Sarah K Sharman; Yali Hou; Allison E Bridges; Nagendra Singh; Sangmi Kim; Ravindra Kolhe; Jimena Trillo-Tinoco; Paulo C Rodriguez; Franklin G Berger; Subbaramiah Sridhar; Darren D Browning Journal: Cancer Prev Res (Phila) Date: 2017-05-03
Authors: Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman Journal: Expert Rev Clin Pharmacol Date: 2017-04-10 Impact factor: 5.045
Authors: Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman Journal: Expert Rev Precis Med Drug Dev Date: 2021-02-02